Hospital
UPMC Wellsboro
UPMC Wellsboro was paid $2.31M by Medicaid between Dec 2019 and Nov 2024, across 136 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 23% of everything it billed.
33Billing provider infoUPMC WELLSBORO
WELLSBORO, PA 16901
WELLSBORO, PA 16901
33aNPI1427501766assigned 08/03/2016
33bProvider typeCritical Access Hospital
28Total paid$2.31M
24GClaims97,760
24DCodes billed136
24AFirst – last monthDec 2019 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Pennsylvania
Rank by total paid#2 of 12
Median peer was paid$1.19M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 35 | $1K | |
| 2020 | 11,190 | $227K | |
| 2021 | 37,791 | $860K | |
| 2022 | 15,711 | $408K | |
| 2023 | 20,828 | $449K | |
| 2024incomplete | 12,205 | $361K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 23% | 16,220 | 11,193 | $539K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 6,651 | 6,395 | $412K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 11% | 658 | 640 | $258K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.5% | 3,958 | 3,845 | $173K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 1,748 | 1,702 | $122K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 451 | 439 | $77K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 2,798 | 2,713 | $69K |
| G0378 | Hospital observation service, per hour | 2.4% | 63 | 53 | $55K |
| 80053 | Comprehensive metabolic panel | 1.8% | 4,563 | 4,361 | $42K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 7,720 | 7,076 | $35K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 522 | 470 | $34K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 605 | 530 | $34K |
124 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 1,434 | $29K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 404 | $23K |
| 82803 | <1% | 1,107 | $22K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,267 | $22K |
| 80050 | General health panel | <1% | 514 | $21K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,365 | $20K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 838 | $17K |
| 87481 | <1% | 109 | $14K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 180 | $14K |
| 80076 | <1% | 1,883 | $13K | |
| 80061 | Lipid panel | <1% | 988 | $12K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 149 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 307 | $10K |
| 84484 | <1% | 1,174 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 430 | $9K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 251 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 399 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,224 | $8K |
| 83605 | <1% | 1,170 | $8K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 253 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 576 | $7K |
| 81001 | <1% | 2,853 | $7K | |
| 83735 | <1% | 1,092 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 208 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 38 | $5K |
| 85027 | <1% | 771 | $5K | |
| 82375 | <1% | 1,109 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 167 | $5K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 284 | $5K |
| 84702 | <1% | 302 | $4K | |
| 83690 | <1% | 1,068 | $4K | |
| 87186 | <1% | 589 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 296 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 645 | $4K |
| 82607 | <1% | 339 | $4K | |
| 84466 | <1% | 268 | $4K | |
| 87077 | <1% | 599 | $4K | |
| 73564 | <1% | 191 | $4K | |
| 73610 | <1% | 215 | $4K | |
| 81025 | <1% | 950 | $3K | |
| 82728 | <1% | 315 | $3K | |
| 80329 | <1% | 236 | $3K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 114 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 273 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 176 | $3K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 155 | $3K |
| 73630 | <1% | 292 | $3K | |
| 83050 | <1% | 1,107 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 155 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 38 | $3K |
| 11721 | <1% | 429 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 411 | $2K |
| 86803 | <1% | 130 | $2K | |
| 84132 | <1% | 586 | $2K | |
| 87081 | <1% | 439 | $2K | |
| 87040 | <1% | 164 | $2K | |
| 83540 | <1% | 282 | $2K | |
| 85379 | <1% | 199 | $2K | |
| 84439 | <1% | 228 | $2K | |
| 87430 | <1% | 270 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 130 | $1K |
| 85018 | <1% | 643 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 15 | $1K |
| 85610 | <1% | 529 | $1K | |
| 86618 | <1% | 59 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 31 | $1K |
| 84153 | <1% | 57 | $1K | |
| 87070 | <1% | 212 | $1K | |
| 90715 | <1% | 52 | $939.97 | |
| 83880 | <1% | 55 | $878.05 | |
| 82550 | <1% | 148 | $844.23 | |
| 85730 | <1% | 169 | $799.13 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 28 | $796.85 |
| 85652 | <1% | 297 | $786.70 | |
| 73030 | <1% | 54 | $749.88 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,848 | $737.34 |
| 86140 | <1% | 272 | $688.71 | |
| 93226 | <1% | 14 | $584.83 | |
| 82962 | <1% | 325 | $576.20 | |
| 82746 | <1% | 56 | $571.20 | |
| 82043 | <1% | 68 | $492.28 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 41 | $451.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 146 | $417.67 |
| 86780 | <1% | 28 | $414.42 | |
| 86850 | <1% | 69 | $398.23 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 53 | $387.94 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,011 | $324.95 |
| 20610 | <1% | 42 | $322.24 | |
| 73110 | <1% | 29 | $310.15 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 31 | $302.50 |
| 93225 | <1% | 14 | $268.48 | |
| 84550 | <1% | 55 | $257.60 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 634 | $243.76 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,138 | $236.31 |
| 81002 | <1% | 60 | $198.87 | |
| 86592 | <1% | 44 | $168.04 | |
| 86038 | <1% | 13 | $156.00 | |
| 87205 | <1% | 44 | $147.80 | |
| G0008 | Administration of influenza virus vaccine | <1% | 13 | $146.50 |
| 73130 | <1% | 14 | $144.25 | |
| 90670 | <1% | 12 | $132.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,841 | $120.34 |
| 86901 | <1% | 40 | $120.08 | |
| 86900 | <1% | 40 | $118.64 | |
| 92551 | <1% | 14 | $118.37 | |
| 86430 | <1% | 15 | $98.70 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 572 | $87.83 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 983 | $68.49 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 107 | $39.15 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 88 | $16.51 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 136 | $0.78 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 284 | $0.26 |
| J3490 | Unclassified drugs | 0% | 481 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 49 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 52 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 77 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 34 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 202 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 37 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 55 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 69 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 40 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 17 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHILFIGER, JANIE (VP CAO)
Parent organizationUPMC SUSQUEHANNA
| Provider | Location | Paid |
|---|---|---|
| UPMC Wellsboro | Wellsboro, PA | $58K |
| UPMC Wellsboro | Wellsboro, PA | $37K |
| UPMC Wellsboro | Wellsboro, PA | $36K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.